Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.

Novo Nordisk receives the full rights to develop and commercialize the lead program.

Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.

Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.

European vaccine manufacturing is being boosted with high level investments.

There are many promising trials in the pipeline that may bring big news for major therapeutic areas.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Interpreting data and understanding the various components of biologic drug substance testing is an important skillset to know as a lab personnel.

Bristol Myers Squibb has joined Cellares’ Technology Adoption Partnership program just as Cellares launches operations as an integrated development and manufacturing organization.

Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) is approved as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes.

The updated vaccine will be ready to ship following a positive European Commission review.

Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.

The new products aim to aid consumers with menopause and eye health-related issues.

This is the first biosimilar to Tysabri, an injection for adults with multiple sclerosis.

Rentschler Biopharma, CGT Catapult, and Refeyn aim to use automated and digital technologies to improve AAV manufacturing for gene therapies.

The agreement focuses on the research of a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy, owned by Regeneron, designed to enhance proliferation and potency against solid tumors, according to the press release.

Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.

The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.

Royalty Pharma agreed to spend up to $500 million for a 5.1 to 8% royalty on net sales of Ferring’s gene therapy adstiladrin (nadofaragene firadenovec-vcng).

Bright Path will develop and produce APIs for hospitals facing drug shortages in the Capstone Health Alliance.

The formulation will be used to mitigate emerging infectious diseases and public health emergencies.

WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.

FDA has approved a new mAb therapy from Regeneron Pharmaceuticals as well as a higher dose version of Eylea, the company’s eye disease therapeutic.

The immunization, meant to protect infants aged six months or lower, is given to pregnant individuals at a gestation period of 32 to 36 weeks.

Ipsen’s Sohonos (palovarotene) capsules are designed to reduce new, abnormal bone formation in soft and connective tissues in individuals with fibrodysplasia ossificans progressiva, a rare bone disease.

Sartorius’ Biostat STR now incorporates Repligen’s XCell ATF hardware.

The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients.

The deal is worth up to $36 million with an initial upfront consideration of $14 million, with an additional $22 million in contingent value rights (CVRs) that is payable upon achieving certain milestones.